Amarantus Bioscience Holdings Inc (AMBS)

[JLM27]

Stop with this already. Yes dilution hurts, but objectively speaking, the terms really weren't that bad. First, financing a penny stock with no current revenues is off the charts risky. So it's to be expected that the terms would justify that risk for those investing. Secondly, it's amazing that we were able to include a forced execution clause if the stock trades above .10. That means the investors are agreeing to limiting their upside and shows that we have bargaining power. Third, the financiers were insiders who are privy to information that we aren't, which ostensibly was good enough to cause them to want to invest. Finally, the average price of around .03 isn't that low. Yes the stock was trading at .06 when the deal was announced, but don't forget about the several months before that when it was trading at .03. I don't know the 50 DMA at the time of the deal off the top of my head, but it couldn't have been a whole lot north of .03.

The only thing that matters right now is the validation results. In fact, I think people are failing to realize the gravity of this news. This is the first truly game changing piece of news AMBS has ever had. Either we have our first viable product and our first revenues are virtually assured to come in the future, or we don't. That's why I'm dying for Gerald to release the results.